What has to be proved about a method before its numbers can be used: why method validation, method development and validation together, analytical method validation and phase appropriate method validation describe the same discipline scaled to how far a programme has got, what a test method validation exercise must demonstrate in accuracy, precision, specificity, range and robustness, how extractables and leachables, an extractables and leachables analysis, extractables testing, extractable testing, extractables leachables as a pair, leachables, leachables testing, leachables and extractables, leachables and extractables testing, leachable and extractables work, extractables and leachables testing and the fuller extractable and leachable testing in pharmaceutical analysis differ in whether the container was stressed or merely stored, where forced degradation studies produce the degradants a stability indicating method has to resolve, what protein aggregation analysis adds for a biologic, where a mass spectrometry test is the identification arm of the same exercise, and why chromatography standards and mass spectrometry standards are what make any of it traceable

A number from an unvalidated method is an observation. Validation is what turns it into evidence, and it is scaled to the decision the number supports: early development needs a method shown to be fit for purpose, and a filing needs the full exercise. Container studies follow the same logic from the other direction.

current good manufacturing practice for finished pharmaceuticals, 21 CFR
Part 211
laboratory records, the clause behind a batch record
211.194
electronic records and signatures, the clause behind an audit trail
Part 11

The figures in this panel are regulation and standard identifiers, named from the documents themselves and linked below. They are not prices: BioBricks publishes verified prices for synthesis services only, and does not imply a price index it has not measured.

Scoping the work

  1. Scale validation to the phase. Early work needs demonstrated specificity, a working range and repeatability. A filing needs accuracy, intermediate precision, robustness, solution stability and a documented protocol executed as written. Doing the full exercise too early wastes effort; doing it too late delays the filing.
  2. Generate the degradants before validating specificity. A stability indicating method has to separate the product from what it turns into. Forced degradation under acid, base, oxidation, heat and light produces those species so the method can be shown to resolve them.
  3. Separate extractables from leachables. Extractables are what a container can give up under deliberate stress; leachables are what it actually gives up into your product over its shelf life. The first defines what to look for and the second is what has to be controlled.
  4. Choose standards with traceability. Certified reference materials, and system suitability standards run every sequence, are what make a result comparable to anyone else's. Their availability for your analyte is worth checking before the method is designed around them.
  5. Write the protocol before running it. Acceptance criteria decided in advance are what make a validation a validation. Criteria set after the data exist describe the data rather than testing the method.
  6. Plan transfer at the same time. A method that cannot be run elsewhere is a bottleneck. Write it with enough detail for another laboratory, and validate the transfer as a defined exercise rather than as an informal handover.

Acceptance criteria first

The single feature that distinguishes a validation from a characterisation is that criteria were set before the data existed. Everything else follows: the protocol, the sample set, the statistics and what happens if a criterion is missed.

Where a criterion cannot be met, the honest route is a documented deviation and a justification, not a revised criterion applied retrospectively.

Container studies need the real conditions

Leachables depend on the formulation, the contact material, the temperature and the time, and a study run under conditions the product will not experience answers a different question.

Design the study around the real storage and administration path, including any device contact, and run it for the intended shelf life with a stated interim reporting schedule.

Common questions

How much validation does early work need?
Enough to show the method is fit for the decision it supports: specificity, a working range and repeatability, documented. The full exercise belongs later, and doing it early is a common waste.
Why run forced degradation?
To generate the degradation products a stability indicating method has to separate. Without them, specificity cannot be demonstrated against the species that actually matter.
Are extractables and leachables the same study?
No. Extractables are generated by deliberately stressing the container material; leachables are measured in the actual product over its shelf life. The first informs the second and does not replace it.

Get a shortlist for your project

Free. We send a shortlist of vendors whose published prices and service scope fit what you described, built from the verified index on this site. We may email you about this enquiry and similar services from this site; opt out any time, including from the first message.

Browse by service class

Sources

Cite or embed this figure

The median advertised gene synthesis price per base pair in the US research synthesis services market was $0.11 in August 2026, across 4 verified vendor service pages recorded in BioBricks Synthesis Price Index.

Cite as: "BioBricks Synthesis Price Index", updated 2026-08-24, https://biobricks.org/method-validation/.

Embed this figure (plain HTML, no scripts)
median advertised gene synthesis price per base pair · the US research synthesis services market · August 2026

$0.11

Middle 50%$0.07 – $0.15
verified vendor service pages4

Source: BioBricks Synthesis Price Index

Get a vendor shortlistCompare synthesis prices